Drug Pipeline News

FDA fully approves sparsentan for FSGS in children 8 years and older, offering the first targeted option and stronger proteinuria drops than irbesartan.

A review of 6 novel drugs approved by the FDA, with links to coverage from Contemporary Pediatrics and other MJH Life Sciences brands.

The FDA has updated its approval for 1-mg epinephrine nasal spray, removing the age limit to allow all patients weighing at least 33 lb to access the treatment.

A review of 6 drugs approved by the FDA in Q1 2026, with links to coverage from Contemporary Pediatrics.

A review of 4 drugs to be discussed by the US FDA during Q2 2026, with links to coverage from MJH Life Sciences publications.

Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.

The FDA has updated its approval for 1-mg epinephrine nasal spray, removing the age limit to allow all patients weighing at least 33 lb to access the treatment.

This new once-weekly intravenous therapy aims to treat the neurologic manifestations of Hunter syndrome in young children.

Palynziq provides a significant new genotype-independent therapy for patients 12 years and older to help manage and reduce blood phenylalanine levels.

A first-of-its-kind approval for hypothalamic obesity offers earlier, targeted treatment in children.

FDA green-lights Imcivree for acquired hypothalamic obesity in patients 4 years and older, delivering major reductions in BMI and hunger in phase 3.

Aristides Maniatis, MD, FAAP explains how Sogroya reduces treatment burden and improves adherence for pediatric patients with growth disorders.

The FDA sanctioned Johnson & Johnson’s once-daily oral pill for adults and adolescents with moderate to severe plaque psoriasis.

Secukinumab now treats moderate to severe hidradenitis suppurativa in patients 12 years and older, making it the first IL‑17A biologic option for teens.

The approval marks the first treatment option for patients with this rare condition.

The expanded approval provides young pediatric patients with a proven, effective treatment to significantly reduce dangerously high LDL-C levels.

The approval offers a new genotype-independent treatment option for patients aged 12 years and older, significantly reducing blood phenylalanine levels.

FDA okays once-weekly navepegritide for children with achondroplasia, boosting growth with strong trial data; rollout expected early Q2 2026.

The FDA has approved once-weekly somapacitan-beco for children aged 2.5 years and older with 3 separate growth indications.

The FDA has approved desmopressin acetate, the first formulation designed for individualized dosing in patients with central diabetes insipidus.

The approval marks the first FDA-authorized treatment for allergic fungal rhinosinusitis, with trial data showing significant improvements in outcome measures.

The gadopiclenol extension for use in infants and neonates offers high-quality MRI contrast enhancement at half the standard gadolinium dose.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Phase 3 KEPLER data showed vedolizumab achieved remission in nearly half of children with ulcerative colitis, with consistent safety and durable benefit.

FDA expands pitolisant indication to include cataplexy in patients 6 years and older with narcolepsy.